Skip to main content

Abstract

Objective:

The study’s objective was to examine Canadian and Australian community pharmacists’ experiences with people at risk of suicide.

Methods:

A survey was developed and administered online. Countries were compared by Fisher’s exact and t tests. Multivariable logistic-regression analysis was used to identify variables associated with preparedness to help someone in a suicidal crisis.

Results:

The survey was completed by 235 Canadian and 161 Australian pharmacists. Most (85%) interacted with someone at risk of suicide at least once, and 66% experienced voluntary patient disclosure of suicidal thoughts. More Australians than Canadians had mental health crisis training (p<0.001). Preparedness to help in a suicidal crisis was negatively associated with being Canadian, having a patient who died by suicide, lacking training and confidence, and permissive attitudes toward suicide.

Conclusions:

Several perceived barriers impede pharmacists’ abilities to help patients who voluntarily disclose suicidal thoughts. Gatekeeper and related suicide prevention strategy training for community pharmacists is warranted.

HIGHLIGHTS

Because people voluntarily disclose information to community pharmacists regarding suicidal thoughts, plans, and attempts, inclusion and integration of pharmacists’ roles in various suicide prevention framework strategies is warranted.
Pharmacists inquire more frequently about patients’ suicide-related thoughts but less about plans, whether patients intend to carry out such plans, and whether they have the means to carry out such plans.
Barriers such as lack of training may influence pharmacists’ preparedness to directly help someone in a suicidal crisis.
Past suicide attempt is a leading risk factor for suicide, and most suicide attempts involve an overdose of prescription or nonprescription medications (1). Community pharmacists are responsible for the safe and judicious distribution of these medications, which provides them with the opportunity to intervene when presented with someone at risk of suicide (2). Although this has long been recognized as an important role of pharmacists and community pharmacies, research regarding this role is limited (38). To determine pharmacists’ experiences with supporting patients with suicidal thoughts, plans, and attempts, we conducted a two-country survey.

Methods

An online survey using Opinio (https://surveys.dal.ca) was developed and administered to Canadian and Australian community pharmacists. The survey had four sections: general demographic characteristics, the Attitudes Toward Suicide (ATTS) (9) scale, the Stigma of Suicide Scale (SOSS) (10), and a section to collect data on pharmacists’ experiences with patients at risk of suicide or who had died by suicide. The SOSS analysis is complete (8), and the ATTS analysis is underway. This collaboration among investigators from both countries occurred as a result of a shared interest in examining and advancing mental illness and addictions care in community pharmacy settings.

Ethical Approval

The study was approved by the Dalhousie University (2016–3832) and the University of Sydney (2016/464) research ethics boards.

Target Sample and Recruitment

Community pharmacists in Canada and Australia were eligible. Recruitment occurred from June 2016 to April 2017 via e-mail, direct telephone contact, social media, and word of mouth and at professional meetings. We contacted provincial and state professional associations, who then shared the invitation to participate in the survey with their members. We also contacted local pharmacy groups directly and informed pharmacy conference attendees about the survey. When possible, up to two reminders were sent. Pharmacists were offered entry in a gift card draw ($150 [Canadian]) for participation.

Sample Size

A sample of 300 participants (N=150 per country) was calculated to support a 95% confidence interval of no greater than ±6% for our survey estimates of the proportion of responses for each descriptive statistic.

Data Analysis

Descriptive statistics were used to characterize demographics. Continuous data were summarized as means and standard deviations, and categorical data were presented as frequencies with percentages. Comparisons between countries were made by using Fisher’s exact test and t test as appropriate. Multivariable logistic regression was used to determine the relationship between variables and pharmacists’ preparedness to help a person in a suicidal crisis (a complete list of the variables included in the regression analysis is available as an online supplement to this report). Logistic model assumptions were assessed with Hosmer and Lemeshow goodness of fit. All analyses were performed by using SAS, version 9.4, with an alpha level of 0.05. Only significant results from the regression are reported in the text.

Results

Of the 396 pharmacist respondents, 235 were from Canada and 161 were from Australia. Most respondents were female (N=276, 70%) and currently practicing in community pharmacy (N=343, 87%). Significantly more Australian (N=46, 29%) than Canadian (N=27, 12%) pharmacists reported completing training for supporting people in a mental health crisis (p<0.001). Forty-seven percent (N=110) of Canadian and 41% (N=66) of Australian pharmacists reported directly interacting on at least three or more occasions with people they thought were at risk of suicide. In both countries, nearly one in 10 pharmacists reported having interacted with someone at risk of suicide more than 10 times (a full tabulation of participant demographic characteristics and their experiences with patients at risk of suicide can be found in the online supplement).
Three hundred twenty-four pharmacists provided information on their most prominent experience with someone at risk of suicide. What constituted the most prominent experience was left to the respondent’s interpretation. Most pharmacists (N=213, 66%) reported that concerns arose for the patient because the patient directly indicated having thoughts of suicide. Fewer pharmacists (N=44, 14%) directly inquired to ascertain this information. In assessing the person, most pharmacists (N=244, 75%) determined the existence of thoughts of suicide, but approximately 40% or fewer inquired about plans, intentions to carry out plans, and access to means to carry out plans. Approximately 60% (N=194) of the sample reported feeling uncomfortable to very uncomfortable about their involvement after the situation, and 25% (N=81) felt dissatisfied to very dissatisfied with their management of the situation.
Lack of training and not knowing what to do (N=243 [65%] and N=234 [63%], respectively; total, N=371) were viewed as moderate to significant barriers to supporting or caring for a patient perceived to be at risk of suicide. Overall, 43% (N=161) of the 371 pharmacists who responded regarding barriers reported lack of confidence as a moderate to significant barrier. Lack of time was endorsed less often as an important barrier. Lack of private space was more often an issue for Australian respondents (for details, see the online supplement).
Approximately 58% (N=228) of 395 pharmacists strongly agreed or agreed that they were prepared to help a person in a suicidal crisis. In the multivariable regression analysis, being Canadian (odds ratio [OR]=0.13, 95% confidence interval [CI]=0.06–0.27; p≤0.001), having a patient who died by suicide (OR=0.48, 95% CI=0.23–1.00; p=0.049), lacking training (OR=0.42, 95% CI=0.18–0.97; p=0.043), lacking confidence (OR=0.33, 95% CI=0.16–0.69; p=0.003), and permissive attitudes toward suicide (OR=0.92, 95% CI=0.87–0.97; p<.001) were negatively associated with preparedness to help someone in a suicidal crisis. The belief that suicide is preventable was positively associated with being prepared to help a person in a suicidal crisis (OR=1.45, 95% CI=1.30–1.62; p<.001).

Discussion

Most pharmacists (N=335, 85%) in our sample reported interacting at least once with someone at risk of suicide, which is significantly higher than self-reports from recent research (7). Nearly two-thirds of disclosures regarding suicidal thoughts were volunteered by patients to pharmacists. This finding has direct implications for suicide prevention frameworks. Restricting lethal means (e.g., medications) is fundamental to suicide prevention (11), and pharmacists can have a direct role in this risk mitigation strategy. However, when patients disclosed suicidal thoughts, pharmacists’ information gathering focused on those thoughts and less on patients’ plans, intentions to carry out plans, and means to follow through on plans.
The interpretation of self-reported data on experiences obtained via survey methods has inherent limitations, including the potential for biases (e.g., self-selection bias, nonresponder bias). Nonetheless, these findings generate important questions about whether pharmacists know what to do and when to intervene and whether they have the confidence, knowledge, and skills to act when someone discloses suicidal thinking, plans, behaviors, and access to means. Lack of confidence was reported by more Australian pharmacists as a moderate to significant barrier to supporting or caring for someone at risk of suicide, and this variable was negatively associated with perceived preparedness to help someone in a suicidal crisis. Pharmacists’ confidence issues have previously been reported for difficulties starting conversations and intervening with people at risk of suicide (2). Other researchers have reported that pharmacists may prefer a more secondary role in suicide prevention (7), which may, in part, be the result of a lack of confidence. More than 60% of our sample reported not knowing what to do as a moderate to significant barrier to supporting or caring for someone at risk of suicide. However, unlike lack of training, not knowing what to do was not associated with pharmacists’ perceptions of preparedness to help someone in a suicidal crisis. More Australian pharmacists reported some form of training to support people in a mental health crisis, albeit not suicide specific. Notably, in the multivariable analysis, being Australian was positively associated with perceptions of preparedness to help someone in a suicidal crisis.
Education and training are typically the most commonly used interventions for overcoming concerns with lack of training and confidence, but they have mixed effects among pharmacists. For example, previous suicide prevention training for pharmacists in one U.S. state was associated with less confidence in identifying the signs of suicide risk (4). A recent literature synthesis in this area further demonstrated that education and training in suicide may have a positive impact on health care professionals’ knowledge of, confidence in preventing, and attitudes toward suicide, but the impact on behaviors and patient outcomes remains unknown (12). The potential for discordant relationships among these variables (e.g., confidence, knowledge) compared with behaviors is well known (12) and can be demonstrated through the use of objective evaluation measures (e.g., simulated patients). For example, El-Den et al. (5) surveyed pharmacy students after suicide education and training. The majority of students had an inflated level of confidence, which contrasted with their ability to consistently use appropriate terminology when inquiring about suicide in a simulated patient scenario (5).
Gatekeeper training is recommended in suicide prevention frameworks (13) and in regional prevention approaches in various countries (14) as an important prevention strategy, although controversy exists and some uncertainties remain regarding its benefits (15). Gatekeepers are those “likely to come into contact with at-risk individuals . . . influential in a suicidal person’s decision to access care . . . [and] in a position to carry out informal observation of an individual, detect risk, and provide assistance” (13). Suicide-specific gatekeeper training for pharmacists and pharmacy teams (e.g., technicians, assistants) and related changes to community pharmacy environments and practices that support suicide prevention should be developed and evaluated. The pedagogical approach to pharmacy team gatekeeper training requires consideration because exploration of mechanisms to incorporate and address pharmacists’ previous experiences with patients who have died by suicide and pharmacists’ attitudes (e.g., beliefs about whether suicide is preventable and permissible) is important. On the basis of our results, these factors may be associated with perceived preparedness to help someone in a suicidal crisis. Using simulated patients with lived experience of suicidal thinking, plans, and behaviors is a promising method for facilitating meaningful feedback on skills and behaviors and for supporting sustained retention of knowledge among pharmacists (6).
Last, gatekeeper training is but one component of suicide prevention frameworks (11, 13) and should be implemented for pharmacists and other primary care providers in the context of a comprehensive suicide prevention framework with evidence-based strategies (e.g., means restriction). Evaluation of the impact of suicide gatekeeper training for pharmacists and its impact on patients and pharmacists over time is also required.

Conclusions

People voluntarily disclose thoughts of suicide to pharmacists. Most pharmacists in our sample reported interacting with someone at risk of suicide on at least one occasion. Pharmacists inquired more often about suicidal thoughts than about plans, intentions to carry them out, and means to follow through. The role of pharmacists in suicide prevention frameworks needs to be better defined and integrated in light of these results, with a consideration for implementing gatekeeper education and training to build capacity within the profession. More work is required to understand pharmacists’ motivations to engage in assessing those who disclose suicidal thinking and whether their assessments and interventions align with best practices. Interventions to increase pharmacists’ core competencies in suicide prevention should be implemented with ongoing evaluation regarding their impacts.

Supplementary Material

File (appi.ps.201900244.ds001.pdf)

References

1.
Finkelstein Y, Macdonald EM, Hollands S, et al: Repetition of intentional drug overdose: a population-based study. Clin Toxicol (Phila) 2016; 54:585–589
2.
Murphy AL, Ataya R, Himmelman D, et al: Community pharmacists’ experiences and people at risk of suicide in Canada and Australia: a thematic analysis. Soc Psychiatry Psychiatr Epidemiol 2018; 53:1173–1184
3.
Gibson MR, Lott RS: Suicide and the role of the pharmacist. J Am Pharmaceutical Assoc 1972; 12:457–466
4.
Painter NA, Kuo GM, Collins SP, et al: Pharmacist training in suicide prevention. J Am Pharm Assoc (2003) 2018; 58:199–204.e2
5.
El-Den S, Chen TF, Moles R, et al: Assessing mental health first aid skills using simulated patients: exploring observed behaviors. Am J Pharm Educ 2018; 82:185–193
6.
Boukouvalas EA, El-Den S, Chen TF, et al: Confidence and attitudes of pharmacy students towards suicidal crises: patient simulation using people with a lived experience. Soc Psychiatry Psychiatr Epidemiol 2018; 53:1185–1195
7.
Cates ME, Hodges JRC, Woolley TW: Pharmacists’ attitudes, interest, and perceived skills regarding suicide prevention. Ment Health Clin 2019; 9:30–35
8.
Murphy AL, O’Reilly CL, Ataya R, et al: A survey of Canadian and Australian pharmacists’ stigma of suicide. SAGE Open Med 2019; 7:2050312118820344. doi:
9.
Renberg ES, Jacobsson L: Development of a questionnaire on attitudes towards suicide (ATTS) and its application in a Swedish population. Suicide Life Threat Behav 2003; 33:52–64
10.
Batterham PJ, Calear AL, Christensen H: The Stigma of Suicide Scale. Psychometric properties and correlates of the stigma of suicide. Crisis 2013; 34:13–21
11.
Zalsman G, Hawton K, Wasserman D, et al: Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 2016; 3:646–659
12.
Boukouvalas E, El-Den S, Murphy AL, et al: Exploring health care professionals’ knowledge of, attitudes towards and confidence in care for people at risk of suicide: a systematic review. Arch Suicide Res (Epub ahead of print, March 11, 2019)
13.
Ridani R, Torok M, Shand F, et al: An Evidence-Based Systems Approach to Suicide Prevention: Guidance on Planning, Commissioning, and Monitoring. Sydney, New South Wales, Australia, Black Dog Institute, 2016. www.blackdoginstitute.org.au/docs/default-source/research/evidence-and-policy-section/an-evidence-based-systems-approach-to-suicide-prevention.pdf?sfvrsn=0
14.
Hegerl U, Wittenburg L, Arensman E, et al: Optimizing suicide prevention programs and their implementation in Europe (OSPI Europe): an evidence-based multi-level approach. BMC Public Health 2009; 9:428
15.
Yonemoto N, Kawashima Y, Endo K, et al: Gatekeeper training for suicidal behaviors: A systematic review. J Affect Disord 2019; 246:506–514

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 293 - 296
PubMed: 31744430

History

Received: 14 May 2019
Revision received: 20 August 2019
Accepted: 9 September 2019
Published online: 20 November 2019
Published in print: March 01, 2020

Keywords

  1. Suicide and self-destructive behavior
  2. Community mental health services

Authors

Affiliations

Andrea L. Murphy, B.Sc.Pharm., Pharm.D. [email protected]
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Claire L. O’Reilly, B.Pharm., Ph.D.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Randa Ataya, B.Sc.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Steve P. Doucette, M.Sc.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Frederick I. Burge, M.D., F.C.F.P.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Luis Salvador-Carulla, M.D., Ph.D.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Timothy F. Chen, Ph.D.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Dani Himmelman, M.Sc.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Stanley Kutcher, M.D., F.R.C.P.C.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Ruth Martin-Misener, M.N., Ph.D.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
Alan Rosen, A.O., F.R.A.N.Z.C.P.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.
David M. Gardner, M.Sc., Pharm.D.
College of Pharmacy (Murphy, Ataya, Gardner), Department of Psychiatry (Murphy, Kutcher, Gardner), Department of Family Medicine (Burge), and School of Nursing (Martin-Misener), all at Dalhousie University, Halifax, Nova Scotia, Canada; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia (O’Reilly, Chen); Research Methods Unit, Nova Scotia Health Authority, Halifax (Doucette); Centre for Mental Health Research, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory (Salvador-Carulla); Schizophrenia Society of Nova Scotia, Halifax (Himmelman); Brain & Mind Centre, University of Sydney, Sydney (Rosen); Illawarra Institute for Mental Health, University of Wollongong, Wollongong, New South Wales, Australia (Rosen); Independent Senators Group, Senate of Canada, Ottawa, Ontario, Canada (Kutcher). Dr. Kutcher was with IWK Health Centre, Dalhousie University, Halifax, at the time of this study.

Notes

Send correspondence to Dr. Murphy ([email protected]).
Dr. O’Reilly presented the findings from the Australia pharmacists at the Australasian Pharmaceutical Society Association meeting, December 3–5, 2018, Adelaide, Australia.

Competing Interests

The authors report no financial relationships with commercial interests.

Funding Information

This work was supported by research grants from the Dalhousie Pharmacy Endowment Fund (DPEF) and the Pharmacy Council of New South Wales as well as a studentship from the Drug Evaluation Alliance of Nova Scotia (DEANS). The initial meetings for Dr. Murphy and Dr. Gardner to collaborate with Australian colleagues to prepare the DPEF grant proposal were supported by DEANS through sabbatical support for Dr. Murphy and Dr. Gardner.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share